A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

A Single-arm, Multicenter, Open-labeled, Phase II Study on the Efficacy and Safety of Carelizumab Combined With Irinotecan and Apatinib in the Second-line Treatment of Locally Advanced Unresectable, Recurrent or Metastatic Adenocarcinoma of Stomach and Gastroesophageal Junction

The purpose of this study was to evaluate the overall survival time (OS), objective remission rate（ORR）, progression-free survival time（PFS）, disease control rate（DCR）of Carelizumab combined with irinotecan and apatinib for the second-line treatment of locally advanced unresectable, recurrent or metastatic adenocarcinoma of stomach and gastroesophageal junction. At the same time, the safety and tolerance of the scheme were preliminarily evaluated.

Study Overview

• Status: Recruiting
• Conditions: Gastric Cancer
• Intervention / Treatment: Drug: Carelizumab Combined With Irinotecan and Apatinib

• Study Type: Interventional
• Enrollment (Anticipated): 85
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Min Shi; Phone Number: 020-62787736; Email: nfyyshimin@163.com
• Study Contact Backup: Name: Chunlin Wang; Phone Number: 020-62787735; Email: wangchunl03@163.com

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510515
      • Recruiting
      • Nanfang Hospital
      • Contact: Min Shi; Phone Number: 020-62787736; Email: nfyyshimin@163.com
      • Contact: Chunlin Wang; Phone Number: 020-62787735; Email: wangchunl03@163.com
      • Principal Investigator: Min Shi
      • Sub-Investigator: Chunlin Wang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The local advanced stage confirmed by histopathology is unresectable, recurrent or metastatic Adenocarcinoma of stomach and gastroesophageal junction.
2. After receiving first-line treatment, the disease progressed or intolerable adverse reactions occurred.
3. At least one measurable lesion or evaluable lesion (according to RECIST 1.1 standard);
4. Patients agreed to provide blood samples and previously stored tumor tissue samples for tumor microenvironment detection.
5. Age ≥18 years old and ≤75 years old.
6. The ECOG score is 0 or 1.
7. The estimated survival time is ≥3 months.
8. Within 7 days before entering the group, the laboratory test value met the chemotherapy standard.
9. Within 28 days before enrollment, women of childbearing age must confirm that the serum pregnancy test is negative and agree to adopt effective contraceptive measures during the study drug use and within 6 months after the last administration.
10. Patients voluntarily joined the study, signed informed consent, and were able to comply with the visit and related procedures stipulated in the plan.

Exclusion Criteria:

1. Participate in other intervention clinical studies at the same time (unless participating in observation studies or being in the follow-up stage of intervention studies), and have received second-line treatment.
2. have received antibody therapy of PD-1, PD-L1, PD-L2, CTLA4, CD137 or any other antibody or drug therapy with t cell co-stimulation or immune checkpoint pathway as specific target.
3. It is known to be allergic to any monoclonal antibody or adjuvant.
4. Received Chinese patent medicines with anti-tumor indications or drugs with immunoregulatory effects (thymosin, interferon, interleukin, etc.) within 2 weeks before the first administration.
5. Having undergone major surgery within 4 weeks before the first administration or expecting to undergo surgery during the study treatment.
6. Receive live attenuated vaccine within 4 weeks before the first administration or during the planned study treatment.
7. Received transplantation of solid organs or blood system.
8. Active, known or suspected autoimmune diseases or related medical history in the past 2 years (vitiligo, psoriasis, alopecia or Graves' disease that does not require systematic treatment in the past 2 years, hypothyroidism that only requires thyroid hormone replacement therapy, and type I diabetes patients who only need insulin replacement therapy can enter Group).
9. Immunosuppressive drugs have been used within 4 weeks before the first administration, excluding local glucocorticoid by nasal spray, inhalation or other routes or systemic glucocorticoid with physiological dose (i.e., prednisone or other glucocorticoid with equivalent dose not exceeding 10mg/ day), or hormone used due to allergy.
10. Known history of primary immunodeficiency disease.
11. Known history of active tuberculosis. 12 known to have a history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody positive).

13. after regular antihypertensive treatment, the blood pressure still cannot fall to the normal range (systolic blood pressure > >140mmHg, diastolic blood pressure > >90mmHg).

14. ≥II grade ii coronary heart disease and arrhythmia (including QTc interval prolongation > >450ms for men and > >470ms for women).

15. Symptomatic congestive heart failure (new york Heart Association Grade II-IV) or symptomatic or poorly controlled arrhythmia.

16. before the first administration, there was toxicity caused by previous anti-tumor treatment that did not recover to grade 0 or grade 1 of the national cancer institute general adverse event terminology version 4.03 (NCI ctcae version 4.03) (excluding alopecia, fatigue and asymptomatic laboratory abnormalities).

17. abnormal coagulation function (INR > 1.5 uln, aptt > 1.5 uln), with bleeding tendency.

18. It is known that symptomatic central nervous system metastasis exists. 19. Diagnosed as other malignant tumors within 5 years before the first administration, excluding basal cell carcinoma of skin, squamous cell carcinoma of skin and carcinoma in situ after radical resection.

20. Active infections requiring treatment or systemic anti-infective drugs used within 7 days before the first administration.

21. acute or chronic active hepatitis b: HBV viral load ≥500 copies /ml 22. Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before the study.

23. It is known that there are mental diseases or drug abuse situations that may affect the compliance with the test requirements.

24. Acute or chronic active hepatitis C: HCV antibody is positive. 25. Pregnant or lactating women. 26. There are medical histories, diseases, treatments or abnormal laboratory results that may interfere with the test results and prevent the subjects from participating in the study, or the researchers think that participating in the study is not in the best interests of the subjects.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Carelizumab Combined With Irinotecan and Apatinib; Second-line treatment of advanced gastric cancer with three-drug regimen（Carelizumab Combined With Irinotecan and Apatinib ）	Drug: Carelizumab Combined With Irinotecan and Apatinib; Three-drug regimen was used in second-line treatment of Advanced gastric cancer

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Suvival time（OS）	The time from randomization to death due to any reason. For those who have lost follow-up before death, the last follow-up time is usually calculated as the time of death.	Up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progress Free Survival time（PFS）	The time from randomization to the first occurrence of disease progression or death from any cause.	Up to 24 months
objective response rate（ORR）	Refers to the proportion of patients whose tumors have shrunk to a certain amount and kept for a certain time, including CR and PR cases	Up to 24 months
duration of response （DoR）	It is the curative effect evaluation index of tumor reaction, which refers to the time from the first evaluation of complete remission (CR) or partial remission (PR) to the first evaluation of disease progression (PD) or death from any cause	Up to 24 months
Disease control rate（DCR）	The proportion of patients whose tumors have shrunk or remained stable for a certain period of time, including cases of complete remission (CR), partial remission (PR) and stable (SD)	Up to 24 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability	The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v4.03	Up to 24 months

Collaborators and Investigators

• Sponsor: Nanfang Hospital of Southern Medical University
• Investigators: Principal Investigator: Min Shi, Oncology department of Nanfang hospital

Study record dates

Study Major Dates

• Study Start (Actual): May 19, 2020
• Primary Completion (Anticipated): May 19, 2023
• Study Completion (Anticipated): May 19, 2025

Study Registration Dates

• First Submitted: June 12, 2021
• First Submitted That Met QC Criteria: June 20, 2021
• First Posted (Actual): June 22, 2021

Study Record Updates

• Last Update Posted (Actual): June 22, 2021
• Last Update Submitted That Met QC Criteria: June 20, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase Inhibitors; Protein Kinase Inhibitors; Topoisomerase I Inhibitors; Irinotecan; Apatinib
• Other Study ID Numbers: NFEC-2020-024

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No